Farmas USA

yo la he vuelto a poner ahora a $2,40
RGLS
no esperes grandes movimientos hasta el hold lift.

No se que leches pasa con MACK ... pero he comprado al cierre del gap por vela diaria en 3,80.

Aunque parece que quiere cerrar el intradia y todo en 3,6 ...

Ya veremos lo buena idea que es ....

CTIC

Soy sube por update empresarial. La tengo en mente para meterle otro corto. Dilución próxima diría yo.

PIX306 confirmatory trial of our commercial product PIXUVRI(R)(pixantrone) continues to progress toward an announcement of top-line results later this year
In January 2017, CTI BioPharma received a €7.5 million milestone payment from its partner Servier following achievement of a milestone associated with patient enrollment in the Phase 3 PIX306 clinical trial of PIXUVRI. The trial is a post-authorization trial as part of the conditional marketing authorization of PIXUVRI in the European Union (E.U.) The PIX306 is comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell non-Hodgkin lymphoma (NHL). The trial continues to enroll patients.
2017 Key Objectives
Advance Marketing Authorization Application in E.U. and define regulatory pathway in U.S. for pacritinib
dialogue with the European Medicines Authority (EMA) on the Marketing Authorization Application (MAA) for pacritinib that had been previously filed by its former partner, Baxalta
With the availability of results from the PERSIST-2 clinical trial and the recent completion of the PERSIST-2 clinical study report, CTI BioPharma believes that the best strategy currently to achieve marketing authorization is to utilize the combined clinical evidence from both Phase 3 trials. Accordingly, CTI BioPharma is evaluating whether to update the current application with the additional data from PERSIST-2 or to resubmit the MAA.

CTI BioPharma expects to initiate the PAC203 trial in the second quarter of 2017
Secure ex-U.S. partner for pacritinib. CTI BioPharma intends to secure a partnership for the development and commercialization of pacritinib in certain territories outside the U.S.
Release top-line results of PIX306. CTI BioPharma expects to complete enrollment in the ongoing PIX306 trial of PIXUVRI and release top-line results by the end of 2017
balance as of December 31, 2016 is approximately $44.0 million. In January 2017, we received a €7.5 million milestone payment from Servier. CTI BioPharma expects that its cash burn (a non-GAAP financial measure), excluding cash inflows from future business development activities and proceeds from capital markets financing activities, would be approximately $65-75 million for 2017. The Company expects to meet its cash requirements for 2017 with existing cash and by partnering one or more product assets during the course of the year.

ETRM

Parece que ha dejado de ser un chicharro por ahora, pero tiene poco float.

En los últimos días se ha cascado un R/S y ha sacado una noticia de ampliación de de los centros que colocan su dispositivo, lo que ha propiciado un short squeeze digno de ver. Aquí lo dejo. Por supuesto, espero el momento de meterle corto. Agradeceré ideas o fundamentales sobre la bicha.

si, en el otro hilo estan algunos relamiendose cosa fina :)

ETRM

MACK
A ver si dura la remontada

ETRM

Y las heridas también:) de perder 4K pavos a solo 1K8 me doy por contento.
Sali 6,80$

SCON

Aguantando 1,23
Saliste no.. Framus. ¿Como la ves?

si, yo me sali de SCON, como la veo? Que el stop lo tienes clarisimo ahi en 1,15-1,16. Por lo demas, creando suelo es lo que parece a simple vista. Pero no me gusta mantener esos valores a ver si brincan, o lo hacen cuando creo que deben hacerlo ( como ya hizo hasta 1,37 ) ... o me da mucho respeto quedarme al proximo latigazo que a saber por donde va ...  aunque el MACD es positivo, todo hay que decirlo. suerte.